Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Small Cell Lung Cancer
Interventions
DRUG

LBH589 and carboplatin with etoposide

"LBH589 will be given in oral formulation starting at a dose of 10 mg (Dose Level 1) 3x/week (2 days apart, e.g. Mon, Wed, Fri), during 2 weeks out of 3-weekly dosing schedule. After establishing the MTD at a 2 out 3 weeks dosing schedule, a 3 out of 3 weeks dosing schedule will be tested at that dose. This schedule will be adopted in the absence of limiting toxicities. Will be continued weekly after completion of 6 cycles of combo chemotherapy until progression or intolerable toxicities.~Etoposide: Cycles 1-6: 100 mg/m² IV over 60 mins, Days 1-3 every 21 days for 6 cycles Carboplatin: commercially available as a sterile lyophilized powder available in single dose vials containing 50mg, 150mg, or 450mg of carboplatin. Each vial contains equal parts by weight of carboplatin \& mannitol. Commercial supplies will be used for this study. It will be administered as an i.v. infusion over 30 minutes. The dose will be calculated based on patient's body weight at each treatment visit."

Trial Locations (1)

15213

University of Pittsburgh, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Ahmad Tarhini

OTHER